Haptoglobin Reagent Market Outlook:
Haptoglobin Reagent Market size was valued at USD 161.5 million in 2025 and is projected to reach USD 337.8 million by the end of 2035, rising at a CAGR of 7.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of haptoglobin reagents is evaluated at USD 173.7 million.
The heightened demand for diagnostic tools in clinical settings is the key factor behind the robust growth of the market. Besides, healthcare providers across different nations are adopting biochemical reagents such as haptoglobin for accurate measurement of hemolytic anemia and inflammatory conditions. As per an article published by NIH in September 2023, autoimmune hemolytic anemia occurs in around 1 to 3 individuals per 100,000 on a yearly basis. Also, the studies reveal increased one-year mortality ranging from approximately 14% to 28% depending on subtype and underlying conditions.
Furthermore, JMCP in November 2022 reported that cold agglutinin disease causes a considerable economic burden on healthcare systems, which is due to CAD-associated therapies, blood transfusions, and healthcare resource utilization. It also stated that patients with severe anemia reported amplified costs influenced by increased hospitalizations, outpatient visits, emergency department visits, and transfusion requirements, underscoring the strong necessity for haptoglobin reagents.
